Direct inhibitory effects of pioglitazone on hepatic fetuin-A expression.
Fetuin-A, a circulating glycoprotein synthesized in the liver, is involved in insulin resistance and type 2 diabetes. However, regulation of fetuin-A synthesis has remained obscure. We previously reported that pioglitazone treatment significantly reduced serum fetuin-A levels in patients with type 2...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3923806?pdf=render |
id |
doaj-312c5147973f4e859afa30fe022776db |
---|---|
record_format |
Article |
spelling |
doaj-312c5147973f4e859afa30fe022776db2020-11-25T01:59:46ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0192e8870410.1371/journal.pone.0088704Direct inhibitory effects of pioglitazone on hepatic fetuin-A expression.Akinobu OchiKatsuhito MoriMasanori EmotoShinya NakataniTomoaki MoriokaKoka MotoyamaShinya FukumotoYasuo ImanishiHidenori KoyamaEiji IshimuraMasaaki InabaFetuin-A, a circulating glycoprotein synthesized in the liver, is involved in insulin resistance and type 2 diabetes. However, regulation of fetuin-A synthesis has remained obscure. We previously reported that pioglitazone treatment significantly reduced serum fetuin-A levels in patients with type 2 diabetes. To clarify whether pioglitazone can directory inhibit hepatic fetuin-A synthesis, we investigated the effects of pioglitazone on fetuin-A expression both in vitro and in vivo. Pioglitazone treatment suppressed mRNA and protein expression of fetuin-A in Fao hepatoma cells. Interestingly, rosiglitazone but not metformin, also inhibited fetuin-A expression. In addition, GW 9662, an inhibitor of peroxisome proliferator-activated receptor (PPAR) γ, reversed pioglitazone-induced suppression of fetuin-A, suggesting that thiazolidinedione derivatives may have common characteristics with regard to fetuin-A suppression, possibly through PPARγactivation. Finally, oral administration of pioglitazone to mice for 8 weeks resulted in suppression of hepatic fetuin-A mRNA. These findings suggest that pioglitazone may partially ameliorate insulin resistance through its direct inhibitory effects on fetuin-A expression in the liver.http://europepmc.org/articles/PMC3923806?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Akinobu Ochi Katsuhito Mori Masanori Emoto Shinya Nakatani Tomoaki Morioka Koka Motoyama Shinya Fukumoto Yasuo Imanishi Hidenori Koyama Eiji Ishimura Masaaki Inaba |
spellingShingle |
Akinobu Ochi Katsuhito Mori Masanori Emoto Shinya Nakatani Tomoaki Morioka Koka Motoyama Shinya Fukumoto Yasuo Imanishi Hidenori Koyama Eiji Ishimura Masaaki Inaba Direct inhibitory effects of pioglitazone on hepatic fetuin-A expression. PLoS ONE |
author_facet |
Akinobu Ochi Katsuhito Mori Masanori Emoto Shinya Nakatani Tomoaki Morioka Koka Motoyama Shinya Fukumoto Yasuo Imanishi Hidenori Koyama Eiji Ishimura Masaaki Inaba |
author_sort |
Akinobu Ochi |
title |
Direct inhibitory effects of pioglitazone on hepatic fetuin-A expression. |
title_short |
Direct inhibitory effects of pioglitazone on hepatic fetuin-A expression. |
title_full |
Direct inhibitory effects of pioglitazone on hepatic fetuin-A expression. |
title_fullStr |
Direct inhibitory effects of pioglitazone on hepatic fetuin-A expression. |
title_full_unstemmed |
Direct inhibitory effects of pioglitazone on hepatic fetuin-A expression. |
title_sort |
direct inhibitory effects of pioglitazone on hepatic fetuin-a expression. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2014-01-01 |
description |
Fetuin-A, a circulating glycoprotein synthesized in the liver, is involved in insulin resistance and type 2 diabetes. However, regulation of fetuin-A synthesis has remained obscure. We previously reported that pioglitazone treatment significantly reduced serum fetuin-A levels in patients with type 2 diabetes. To clarify whether pioglitazone can directory inhibit hepatic fetuin-A synthesis, we investigated the effects of pioglitazone on fetuin-A expression both in vitro and in vivo. Pioglitazone treatment suppressed mRNA and protein expression of fetuin-A in Fao hepatoma cells. Interestingly, rosiglitazone but not metformin, also inhibited fetuin-A expression. In addition, GW 9662, an inhibitor of peroxisome proliferator-activated receptor (PPAR) γ, reversed pioglitazone-induced suppression of fetuin-A, suggesting that thiazolidinedione derivatives may have common characteristics with regard to fetuin-A suppression, possibly through PPARγactivation. Finally, oral administration of pioglitazone to mice for 8 weeks resulted in suppression of hepatic fetuin-A mRNA. These findings suggest that pioglitazone may partially ameliorate insulin resistance through its direct inhibitory effects on fetuin-A expression in the liver. |
url |
http://europepmc.org/articles/PMC3923806?pdf=render |
work_keys_str_mv |
AT akinobuochi directinhibitoryeffectsofpioglitazoneonhepaticfetuinaexpression AT katsuhitomori directinhibitoryeffectsofpioglitazoneonhepaticfetuinaexpression AT masanoriemoto directinhibitoryeffectsofpioglitazoneonhepaticfetuinaexpression AT shinyanakatani directinhibitoryeffectsofpioglitazoneonhepaticfetuinaexpression AT tomoakimorioka directinhibitoryeffectsofpioglitazoneonhepaticfetuinaexpression AT kokamotoyama directinhibitoryeffectsofpioglitazoneonhepaticfetuinaexpression AT shinyafukumoto directinhibitoryeffectsofpioglitazoneonhepaticfetuinaexpression AT yasuoimanishi directinhibitoryeffectsofpioglitazoneonhepaticfetuinaexpression AT hidenorikoyama directinhibitoryeffectsofpioglitazoneonhepaticfetuinaexpression AT eijiishimura directinhibitoryeffectsofpioglitazoneonhepaticfetuinaexpression AT masaakiinaba directinhibitoryeffectsofpioglitazoneonhepaticfetuinaexpression |
_version_ |
1724962566905528320 |